DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Toprol-XL (Metoprolol Succinate) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The following adverse reactions are described elsewhere in labeling:

•Worsening angina or myocardial infarction.

[see Warnings and Precautions (5) ]

•Worsening heart failure.

[see Warnings and Precautions (5) ]

•Worsening AV block.

[see Contraindications (4) ]

 

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Hypertension and Angina: Most adverse reactions have been mild and transient. The most common (>2%) adverse reactions are tiredness, dizziness, depression, diarrhea, shortness of breath, bradycardia, and rash.

Heart Failure: In the MERIT-HF study comparing TOPROL-XL in daily doses up to 200 mg (mean dose 159 mg once-daily; n=1990) to placebo (n=2001), 10.3% of TOPROL-XL patients discontinued for adverse reactions vs. 12.2% of placebo patients.

The table below lists adverse reactions in the MERIT-HF study that occurred at an incidence of ≥ 1% in the TOPROL-XL group and greater than placebo by more than 0.5%, regardless of the assessment of causality.

Adverse Reactions Occurring in the MERIT-HF Study at an Incidence ≥1% in TOPROL-XL Group and Greater Than Placebo by More than 0.5%

TOPROL-XL

n=1990 % of patients

Placebo

n=2001 % of patients

Dizziness/vertigo

1.8

1.0

Bradycardia

1.5

0.4

Accident and/or injury

1.4

0.8

Post-operative Adverse Events: In a randomized, double-blind, placebo-controlled trial of 8351 patients with or at risk for atherosclerotic disease undergoing non-vascular surgery and who were not taking beta–blocker therapy, TOPROL-XL 100 mg was started 2 to 4 hours prior to surgery then continued for 30 days at 200 mg per day. TOPROL-XL use was associated with a higher incidence of bradycardia (6.6% vs 2.4%; HR, 2.74; 95% CI 2.19, 3.43), hypotension (15% vs. 9.7%; HR 1.55; 95% CI 1.37, 1.74), stroke (1.0% vs 0.5%; HR 2.17; 95% CI 1.26, 3.74) and death (3.1% vs 2.3%; HR 1.33; 95% CI 1,03, 1.74) compared to placebo.

 

The following adverse reactions have been identified during post-approval use of TOPROL-XL or immediate-release metoprolol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: Cold extremities, arterial insufficiency (usually of the Raynaud type), palpitations, peripheral edema, syncope, chest pain and hypotension.

Respiratory: Wheezing (bronchospasm), dyspnea.

Central Nervous System: Confusion, short-term memory loss, headache, somnolence, nightmares, insomnia, anxiety/nervousness, hallucinations, paresthesia.

Gastrointestinal: Nausea, dry mouth, constipation, flatulence, heartburn, hepatitis, vomiting.

Hypersensitive Reactions: Pruritus.

Miscellaneous: Musculoskeletal pain, arthralgia, blurred vision, decreased libido, male impotence, tinnitus, reversible alopecia, agranulocytosis, dry eyes, worsening of psoriasis, Peyronie’s disease, sweating, photosensitivity, taste disturbance.

Potential Adverse Reactions: In addition, there are adverse reactions not listed above that have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to TOPROL-XL.

Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, clouded sensorium, and decreased performance on neuropsychometrics.

Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Hypersensitive Reactions: Laryngospasm, respiratory distress.

 

Clinical laboratory findings may include elevated levels of serum transaminase, alkaline phosphatase, and lactate dehydrogenase.

 



REPORTS OF SUSPECTED TOPROL-XL SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Toprol-XL. The information is not vetted and should not be considered as verified clinical evidence.

Possible Toprol-XL side effects / adverse reactions in 78 year old male

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 78 year old male

Reactions: Colonic Polyp, Polyp, Mass, Lung Neoplasm, Pleural Effusion, Colorectal Cancer, Gastrointestinal Tract Adenoma, Diverticulum Intestinal

Suspect drug(s):
Toprol-XL



Possible Toprol-XL side effects / adverse reactions in 50 year old male

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 50 year old male

Reactions: Death

Adverse event resulted in: death

Suspect drug(s):
Toprol-XL



Possible Toprol-XL side effects / adverse reactions in 63 year old female

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 63 year old female

Reactions: Drug Dose Omission, Dyspnoea, Diabetes Mellitus, Cardiac Arrest, Myocardial Infarction, Cough

Adverse event resulted in: life threatening event, hospitalization

Suspect drug(s):
Toprol-XL
    Administration route: Oral

Symbicort

Prilosec OTC
    Administration route: Oral

Nexium
    Administration route: Oral



See index of all Toprol-XL side effect reports >>

Drug label data at the top of this Page last updated: 2013-10-04

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017